AstraZeneca (AZN) reported strong earnings Friday, including $22 billion, or 4% revenue growth, in the first half of the year, and kept its 2023 forecast stable. Last year, the company saw significant business from its COVID-19 vaccine and antibody treatments through the first half, but this year the company reported a $2 million decline. Excluding COVID, AstraZeneca reported a revenue increase of 16% for the first half of 2023. "Each of our non-COVID-19 therapy areas saw double-digit revenue growth, with eight medicines delivering more than $1 billion of revenue in the first half, demonstrating the strength of our business. Several...